MedTrace Logo

Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients

NCT02462369 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2015-07-28

No results posted yet for this study

Summary

This study compare the effects on microalbuminuria improvement in type 2 diabetes mellitus (T2DM) treated with saxagliptin or glimepiride.All patients received metformin and/or acarbose, and randomly receive saxagliptin (5mg/d) or glimepiride (1-4mg/d).

Conditions

  • Microalbuminuria
  • Microalbuminuria /Creatinine Ratios ACR

Interventions

DRUG

Saxagliptin

DRUG

glimepiride

Sponsors & Collaborators

  • The Second Hospital of Nanjing Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-04-30
Completion
2017-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462369 on ClinicalTrials.gov